|
1
|
Schön MP and Boehncke WH: Psoriasis. N
Engl J Med. 352:2715–1912. 2005. View Article : Google Scholar
|
|
2
|
Lowes MA, Bowcock AM and Krueger JG:
Pathogenesis and therapy of psoriasis. Nature. 445:866–873. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bos JD, de Rie MA, Teunissen MB and Piskin
G: Psoriasis: Dysregulation of innate immunity. Br J Dermatol.
152:1098–1107. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Cesare A, Di Meglio P and Nestle FO:
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J
Invest Dermatol. 129:1339–1350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boniface K, Bernard FX, Garcia M, Gurney
AL, Lecron JC and Morel F: IL-22 inhibits epidermal differentiation
and induces proinflammatory gene expression and migration of human
keratinocytes. J Immunol. 174:3695–3702. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ekman AK, Bivik Eding C, Rundquist I and
Enerbäck C: IL-17 and IL-22 promote keratinocyte stemness in the
germinative compartment in psoriasis. J Invest Dermatol.
139:1564–1573.e8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang M, Ma W, Gao Y, Jia K, Zhang Y, Liu
H and Sun Q: IL-22-induced miR-122-5p promotes keratinocyte
proliferation by targeting Sprouty2. Exp Dermatol. 26:368–374.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boehncke WH: Etiology and pathogenesis of
psoriasis. Rheum Dis Clin North Am. 41:665–675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nestle FO, Kaplan DH and Barker J:
Psoriasis. N Engl J Med. 361:496–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lejeune D, Dumoutier L, Constantinescu S,
Kruijer W, Schuringa JJ and Renauld JC: Interleukin-22 (IL-22)
activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a
rat hepatoma cell line. Pathways that are shared with and distinct
from IL-10. J Biol Chem. 277:33676–33682. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu J, Xiao Z, Zhao R, Lu C and Zhang Y:
Paeoniflorin suppressed IL-22 via p38 MAPK pathway and exerts
anti-psoriatic effect. Life Sci. 180:17–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolk K, Haugen HS, Xu W, Witte E, Waggie
K, Anderson M, Vom Baur E, Witte K, Warszawska K, Philipp S, et al:
IL-22 and IL-20 are key mediators of the epidermal alterations in
psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl).
87:523–536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lopez RG, Garcia-Silva S, Moore SJ,
Bereshchenko O, Martinez-Cruz AB, Ermakova O, Kurz E, Paramio JM
and Nerlov C: C/EBPalpha and beta couple interfollicular
keratinocyte proliferation arrest to commitment and terminal
differentiation. Nat Cell Biol. 11:1181–1190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang ZC, Liu Y, Li SF, Guo L, Zhao Y,
Qian SW, Wen B, Tang QQ and Li X: Suv39h1 mediates AP-2α-dependent
inhibition of C/EBPα expression during adipogenesis. Mol Cell Biol.
34:2330–2338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thompson EA, Zhu S, Hall JR, House JS,
Ranjan R, Burr JA, He YY, Owens DM and Smart RC: C/EBPα expression
is downregulated in human nonmelanoma skin cancers and inactivation
of C/EBPα confers susceptibility to UVB-induced skin squamous cell
carcinomas. J Invest Dermatol. 131:1339–1346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weinstein GD, McCullough JL and Ross PA:
Cell kinetic basis for pathophysiology of psoriasis. J Invest
Dermatol. 85:579–583. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bernard BA, Asselineau D,
Schaffar-Deshayes L and Darmon MY: Abnormal sequence of expression
of differentiation markers in psoriatic epidermis: Inversion of two
steps in the differentiation program? J Invest Dermatol.
90:801–805. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duvic M, Asano AT, Hager C and Mays S: The
pathogenesis of psoriasis and the mechanism of action of
tazarotene. J Am Acad Dermatol. 39:S129–S133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bernerd F, Magnaldo T and Darmon M:
Delayed onset of epidermal differentiation in psoriasis. J Invest
Dermatol. 98:902–910. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sallusto F and Lanzavecchia A:
Heterogeneity of CD4+ memory T cells: Functional modules for
tailored immunity. Eur J Immunol. 39:2076–2082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eyerich S, Eyerich K, Pennino D, Carbone
T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann
C, Behrendt H, et al: Th22 cells represent a distinct human T cell
subset involved in epidermal immunity and remodeling. J Clin
Invest. 119:3573–3585. 2009.PubMed/NCBI
|
|
22
|
Zenewicz LA and Flavell RA: IL-22 and
inflammation: Leukin′ through a glass onion. Eur J Immunol.
38:3265–3268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie MH, Aggarwal S, Ho WH, Foster J, Zhang
Z, Stinson J, Wood WI, Goddard AD and Gurney AL: Interleukin
(IL)-22, a novel human cytokine that signals through the interferon
receptor-related proteins CRF2-4 and IL-22R. J Biol Chem.
275:31335–31339. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma HL, Liang S, Li J, Napierata L, Brown
T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M,
et al: IL-22 is required for Th17 cell-mediated pathology in a
mouse model of psoriasis-like skin inflammation. J Clin Invest.
118:597–607. 2008.PubMed/NCBI
|
|
25
|
Weber GF, Gaertner FC, Erl W, Janssen KP,
Blechert B, Holzmann B, Weighardt H and Essler M: IL-22-mediated
tumor growth reduction correlates with inhibition of ERK1/2 and AKT
phosphorylation and induction of cell cycle arrest in the G2-M
phase. J Immunol. 177:8266–8272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johansen C, Kragballe K, Westergaard M,
Henningsen J, Kristiansen K and Iversen L: The mitogen-activated
protein kinases p38 and ERK1/2 are increased in lesional psoriatic
skin. Br J Dermatol. 152:37–42. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Yang D, Ma S and Liu H:
Up-regulation of activities of mitogen-activated protein kinase in
psoriatic lesions. J Dermatol Sci. 37:118–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Funding AT, Johansen C, Kragballe K and
Iversen L: Mitogen- and stress-activated protein kinase 2 and
cyclic AMP response element binding protein are activated in
lesional psoriatic epidermis. J Invest Dermatol. 127:2012–2019.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson PF and McKnight SL: Eukaryotic
transcriptional regulatory proteins. Annu Rev Biochem. 58:799–839.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maytin EV and Habener JF: Transcription
factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed
during the differentiation program of keratinocytes in vitro and in
vivo. J Invest Dermatol. 110:238–246. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oh HS and Smart RC: Expression of
CCAAT/enhancer binding proteins (C/EBP) is associated with squamous
differentiation in epidermis and isolated primary keratinocytes and
is altered in skin neoplasms. J Invest Dermatol. 110:939–945. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Loomis KD, Zhu S, Yoon K, Johnson PF and
Smart RC: Genetic ablation of CCAAT/enhancer binding protein alpha
in epidermis reveals its role in suppression of epithelial
tumorigenesis. Cancer Res. 67:6768–6776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McKnight SL: McBindall-a better name for
CCAAT/enhancer binding proteins? Cell. 107:259–261. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang H, Iakova P, Wilde M, Welm A, Goode
T, Roesler WJ and Timchenko NA: C/EBPalpha arrests cell
proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell.
8:817–828. 2001. View Article : Google Scholar : PubMed/NCBI
|
